Healthcare has been one of the market’s most overlooked corners in 2026, even as broader indexes push higher across other sectors.
The Health Care Select Sector SPDR Fund (NYSEARCA: XLV) remains down approximately 1% year to date, a stark contrast to the performance seen elsewhere in the market.
A modest 6% bounce over the past month has done little to close the gap between healthcare valuations and the broader market’s momentum.
That prolonged stagnation has created an unusual dynamic where several high-margin operators are trading at forward multiples that appear misaligned with their underlying cash generation.
Investors willing to look past short-term sector weakness may find a window of opportunity that the broader market has so far chosen to ignore.
Healthcare companies with strong free cash flow profiles are historically among the most resilient holdings during periods of broader economic uncertainty or volatility.
When a sector underperforms for months despite solid fundamentals at the company level, it tends to attract value-oriented investors seeking discounted entry points.
The divergence between XLV’s flat performance and the cash generation capacity of its constituent companies is the kind of setup that long-term investors typically find compelling.
Forward price-to-earnings multiples across parts of the healthcare space currently look out of step with the profitability and margin profiles many of these businesses continue to deliver.
Identifying high-quality operators trading at a discount within a lagging sector is a well-established strategy for generating above-average returns once sentiment eventually shifts.
Healthcare’s underperformance in 2026 may ultimately prove to be a setup rather than a signal, with selective stock-picking offering more reward than the sector ETF alone suggests.
Investors looking for value in a market that has grown expensive in many areas would do well to keep the healthcare sector, and XLV’s individual holdings, firmly on their radar this month.
